- Timothy J Wilt, professor of medicine1,
- Ian M Thompson, professor and chair, department of urology2
- 1Minneapolis VA Center for Chronic Disease Outcomes Research, 1 Veterans Drive (111-0), Minneapolis, MN 55417, USA
- 2University of Texas Health Science Center, San Antonio, USA
- Correspondence to: T J Wilt Tim.wilt{at}med.va.gov
Prostate cancer is the most commonly diagnosed cancer in United Kingdom men.w1 In 2002 it was diagnosed in 32 000 men, and more than 10 000 deaths were attributed to it. Its incidence increased with the introduction of the prostate specific antigen (PSA) blood test, and disease specific mortality has declined. This review provides evidence about risk factors, prevention, detection, natural course, and treatment, with a focus on clinically localised disease, to guide primary care doctors.
Summary points
-
Prostate cancer is a common and potentially serious disease
-
Risk factors include increasing age, family history of prostate cancer, and black race. There are few established prevention strategies
-
Early detection and treatment may prevent future cancer-related illness, extend life, and provide peace of mind
-
However, prostate cancer testing, by digital rectal examination and prostate specific antigen testing, can have false positive and false negative results and detects many cancers that would never cause symptoms.
-
Lower urinary symptoms such as frequency, hesitancy, night time urination, and slow stream do not increase prostate cancer risk but are associated with higher PSA values
-
The probability that further evaluation with a prostate biopsy will be required as a result of testing is relatively high. Biopsy can cause adverse effects including pain, bleeding, and urinary infection
-
Treatment options include observation, surgery, radiation, and early hormonal deprivation. Aggressive treatment is needed to realise any benefit from discovery of a tumour, but such treatment may not be necessary or effective
-
Treatment is associated with a small risk of death and a higher risk of side effects, particularly regarding sexual, urinary, and bowel function
-
Men with a life expectancy of <10-15 years (due to advanced age or a serious coexisting condition) are unlikely to benefit from routine testing
Data sources and selection criteria
-
We searched Medline and the Cochrane Library during August 2006 for randomised trials, systematic reviews, …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
The decline in the breast cancer incidence is 1.2% and it is not significant.
Published 10 February 2012
'twas ever thus
Published 10 February 2012
The value of historic human remains
Published 10 February 2012
In Praise of British Literature
Published 10 February 2012
Is real shared decision making possible?
Published 10 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (7 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (7 responses)
Published 1 Feb 2012
Search for evidence goes on (5 responses)
Published 17 Jan 2012